29results about How to "Reduce systemic toxicity" patented technology

The preparation method comprises the following steps: mixing a tannic acid solution and a tetravalent cerium salt solution, adjusting the pH value to 9-11, and reacting to obtain the cerium tannate nano-enzyme, the molar ratio of the tannic acid to the tetravalent cerium salt is (1-4): 1; the hydration dynamic diameter of the cerium tannate nano-enzyme is 20 to 80 nm. The TA-Ce nano-enzyme prepared by the preparation method disclosed by the invention is smaller in particle size, can keep stable and good dispersibility in a physiological environment, and has good biocompatibility, low hemolysis rate and small systemic toxicity; meanwhile, the compound has good kidney targeting property, can be effectively enriched into the injured kidney, eliminates various ROS (reactive oxygen species) and relieves oxidative stress by utilizing unique redox cycle between Ce < 3 + > and Ce < 4 + > states, and has a good effect in treating acute kidney injury induced by rhabdomyolysis and / or cis-platinum. The research lays a foundation for the metal polyphenol nano material in the treatment of acute kidney injury.

The invention relates to the technical field of medicine, in particular to a preparation method and application of a photodynamic-chemotherapy nano platform targeting tumor endogenous YAP1. The nano platform is hollow mesoporous silica nanoparticles (M (at) O-VNPs) loaded with oxaliplatin and VP of a macrophage membrane coating. The preparation method comprises the following steps: S1, synthesizing hollow mesoporous silica nanoparticles; s2, preparing the organic silicon nanoparticles loaded with the Verteporfin, and preparing the organic silicon nanoparticles loaded with the Verteporfin; s3, loading of the oxaliplatin; and S4, extraction and coating of a macrophage membrane. According to the invention, the macrophage membrane wrapped on the surface of the nano platform is utilized to provide good tumor targeting for the M (at) O-VNPs, and by camouflaging the macrophage membrane and the M (at) O-VNPs, not only are recognition and removal of an organism immune system successfully avoided, but also Verteporfin (VP) and oxaliplatin (OXA) can be delivered to a tumor site in a targeting manner, so that the tumor targeting of the drug is remarkably enhanced, and the drug has a good application prospect. The non-specific distribution in healthy tissues is reduced, and the systemic toxicity is reduced.

The invention provides a pharmaceutical composition for treating liver cancer through arterial embolism, the pharmaceutical composition is composed of iodine oil and tirapazamine-loaded nano-vesicles, and the tirapazamine-loaded nano-vesicles comprise nano-vesicles and tirapazamine coated in the inner cores of the nano-vesicles. The invention also provides a preparation method and application of the pharmaceutical composition for treating liver cancer by arterial embolism, the preparation method comprises the following steps: performing liver left artery microcatheter hyperselection on a test rabbit VX2 liver cancer model through in-vivo test, then confirming tumor responsible blood vessels by radiography, and then applying the iodophol and tirapazamine-loaded nano-vesicle compound for embolism until thorough embolism is realized, thereby obtaining the pharmaceutical composition for treating liver cancer by arterial embolism. According to the present invention, the application of the iodophol and the tirapazamine-loaded nano-vesicle compound in the treatment of liver cancer by TAE is safe and effective, the combination with TAE provides the strong synergistic anti-tumor effect, and the TPZ can be promoted to the deep tumor under the action of the UTMD so as to induce the apoptosis of the hypoxia tumor cells;

The invention relates to the technical field of medical application, in particular to a liver-targeted chemotherapeutic drug nano-micelle preparation method, a chemotherapeutic drug and application, and the preparation method comprises the following steps: S100, preparing pluronic-succinimide formate; s200, preparing a pluronic-polyethyleneimine copolymer; s300, preparing divinyl sebacate; carrying out enzymatic synthesis on the Pluronic F127-SE; the preparation method comprises the following steps: preparing a Pluronic F127-C8-GalNAc nano micelle; and preparing the GalNAc (at) LFT-MMs / siCOP1 compound. The preparation method disclosed by the invention is beneficial to rapidly preparing the nano-micelle with multiple effects of active targeting, chemotherapy and gene therapy.

The invention discloses an application of targeted improvement of a high-potassium microenvironment in osteosarcoma immunotherapy, vanadium disulfide nano-particles are synthesized by taking vanadyl acetylacetonate as a raw material and adopting a high-temperature oil phase method, the particles can be accelerated to decompose at 42 DEG C or above so as to release hydrogen sulfide and vanadate, the vanadate can be specifically combined with E2 conformation of Na < + >-K < + >-ATP enzyme, and thus the stability of the particles is improved. According to the present invention, the HSP protein is released, the conversion of the HSP protein to E1 conformation is blocked, the continuous inward flow of K < + > is inhibited, such that the potassium ion concentration in the T cell is reduced, the function inhibition on the T cell is relieved, and the released hydrogen sulfide can further enhance the thermal effect by inhibiting the HSP protein so as to form the ion regulation-immune activation dual mechanism to improve the T cell killing ability. According to the scheme, the high potassium ion level of the osteosarcoma microenvironment is regulated and controlled through vanadate, hydrogen sulfide can enhance immune response and improve the anti-tumor function of T cells by enhancing the heat effect and the synergistic effect of vanadate, and an efficient and low-toxicity new strategy is provided for osteosarcoma treatment.

The invention discloses a brain-targeted nasal-spray amphotericin B phospholipid complex and a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations, the brain-targeted nasal-spray amphotericin B phospholipid complex is prepared by adopting a film dispersion method, and the preparation method comprises the following steps: dissolving 15-hydroxystearic acid polyethylene glycol ester, phospholipid, cholesterol, amphotericin B and optional other auxiliary components in a solvent, removing the solvent until a film is formed, and drying to obtain the brain-targeted nasal-spray amphotericin B phospholipid complex. And carrying out hydration dispersion to obtain the amphotericin B-loaded phospholipid complex. According to the amphotericin B sodium deoxycholate injection, the problems that the traditional amphotericin B sodium deoxycholate injection is high in renal toxicity, the intrathecal injection is poor in solubility, and low in bioavailability and patient compliance, large in side effect and the like due to the fact that the traditional amphotericin B sodium deoxycholate injection is difficult to penetrate through a blood brain After nasal administration, the drug is quickly delivered into the brain, so that the slow release of the drug is realized, the intracerebral bioavailability of the drug is improved, high brain targeting and low systemic toxic and side effects are realized, and good clinical application value and market prospect are achieved.

The invention provides a personalized cancer vaccine based on apoptosis vesicles and a preparation method and application thereof, and belongs to the technical field of biological medicine, the personalized cancer vaccine comprises apoptosis vesicles, an immunologic stimulant and a biocompatibility carrier; the apoptosis vesicles are extracellular vesicles generated after tumor cells are subjected to apoptosis induction; the biocompatible carrier is a modified chitosan hydrogel, and the biocompatible carrier is a modified chitosan hydrogel; the immunologic stimulant is loaded in the apoptosis vesicle, and the apoptosis vesicle loaded with the immunologic stimulant is embedded into the modified chitosan hydrogel. According to the invention, apoptosis vesicles generated by induction of tumor cells of a patient are taken as a core, the apoptosis vesicles have a natural tumor antigen library and a strong immune activation capability, and personalized precise treatment can be realized; meanwhile, the invention provides a preparation method and application in postoperative tumor recurrence prevention and treatment, and provides technical support for clinical transformation.

The invention discloses Fe (at) MoS2 hydrogel for sensitizing immunotherapy and a preparation method of the Fe (at) MoS2 hydrogel. The hydrogel comprises ferrous sulfate, molybdenum disulfide and a hyaluronic acid hydrogel matrix. The hydrogel can continuously release iron ions in a tumor slightly acidic environment, Fe is reduced into Fe by utilizing the catalytic action of MoS, and circular supply of Fe is realized, so that tumor cells are efficiently and enduringly induced to generate ferroptosis. More importantly, it is found that the Fe-coated MoShydrogel can specifically up-regulate expression of IL-36 gamma and CXCL2 in a tumor microenvironment for the first time, and by activating an IL36 gamma / CXCL2 / CXCR2 signal axis, mononuclear macrophages are recruited and remodeled, and the immunosuppression microenvironment is reversed. In-vivo experiments show that when the hydrogel is combined with an immune checkpoint inhibitor (such as an alphaPD-1 antibody), a remarkable synergistic anti-tumor effect can be generated, and the complete remission rate is greatly improved.

The invention relates to HIF-1alpha siRNA lipid nanoparticles and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: S1, dissolving ionizable lipid, neutral lipid, cholesterol and pegylated lipid in an organic solvent to obtain an oil phase; the method comprises the following steps: dissolving HIF-1alpha siRNA in a first buffer solution to obtain a water phase; s2, mixing the oil phase and the water phase by adopting a micro-fluidic technology, diluting with a second buffer solution, removing the organic solvent, and concentrating to obtain the HIF-1alpha siRNA lipid nanoparticles, the targeted delivery of the HIF-1alpha siRNA is realized, so that the HIF-1alpha siRNA is effectively delivered to the rheumatoid arthritis diseased region through the delivery system to play a therapeutic role.

The invention belongs to the technical field of pharmaceutical preparations, and relates to a multi-cell targeting and multi-drug delivery nano-platform aiming at inflammation-related diseases and a preparation method of the multi-cell targeting and multi-drug delivery nano-platform. The nano platform comprises an inflammation response core polydopamine, a delivered drug, a synthesized polymer skeleton and other pharmaceutically acceptable auxiliary materials. The preparation method comprises the following steps: forming polydopamine through oxidative auto-polymerization, synthesizing a drug-loading polymer covalently linked with a drug, mixing, self-assembling to form nanoparticles, and adding a cross-linking agent for enhancing stability to finally prepare the nano platform. The prepared nano platform is good in solubility, strong in stability and high in targeting delivery efficiency, and can effectively perform multi-cell multi-drug targeting delivery for inflammation-related diseases.

The invention provides a nano preparation for preparing a medicine for inhibiting prostatic cancer and a preparation method of the nano preparation, and relates to the technical field of nano medicinal preparations. The nano preparation comprises the following components in parts by mass: traditional Chinese medicine components and a nano carrier, the traditional Chinese medicine component comprises 15-45 parts of a Chinese yam extract, 5-15 parts of a madder extract, 8-20 parts of cuttlebone superfine powder, 10-25 parts of dragon bone superfine powder and 10-25 parts of oyster superfine powder; the nano-carrier comprises 5-20 parts of phospholipid, 2-10 parts of cholesterol, 1-5 parts of fatty acid, 3-15 parts of polyethylene glycol and 1-5 parts of a surfactant. The average particle size of the nano preparation is 80-150 nm, the polydispersity index PDI is smaller than or equal to 0.30, and the encapsulation efficiency is larger than or equal to 75%. According to the invention, active ingredients of traditional Chinese medicines are combined with a nanotechnology, so that the bioavailability and the tumor targeting property are remarkably improved, the pH-responsive release characteristic is achieved, a remarkable inhibition effect on various prostate cancer cell lines is shown, tumor growth can be effectively inhibited, metastasis can be reduced, and a good application prospect is achieved.

The invention discloses a coating method of a colon targeted delivery drug. The method disclosed by the invention comprises the following steps: embedding a medicine coating by utilizing a mixture of starch acetate and gutta-percha; the medicine coating is obtained by coating a medicine with an inner coating material; and the inner packaging material is selected from beta-cyclodextrin, gamma-cyclodextrin, hydroxypropyl-beta-cyclodextrin, chitosan or a chitosan derivative. The release rate of the embedded medicine prepared by the method in gastric juice does not exceed 10%, and the release rate of the embedded medicine in intestinal juice exceeds 30%. Targeted delivery of the medicine in the colon is effectively achieved, toxicity of the medicine to cells is reduced, and excellent biocompatibility is shown.

The invention discloses a composite Chinese medicine preparation for chronic osteomyelitis, and its raw materials include: Wuwei Xiaoduyin extractant, sodium alginate, p-toluenesulfonic acid, cyclodextrin, 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride, emulsifier, chitosan, sodium chloride, calcium chloride; the mass ratio of Wuwei Xiaoduyin extractant, sodium alginate, p-toluenesulfonic acid, cyclodextrin, 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride, emulsifier, chitosan, sodium chloride, and calcium chloride is 10-20: 1-3: 0.1-0.2: 2-8: 0.01-0.1: 0.1-0.2: 1-2: 0.1-0.2: 0.1-0.2. The invention also discloses a preparation method of the composite Chinese medicine preparation for chronic osteomyelitis. The present invention can not only solve the disadvantage that antibiotics are difficult to penetrate into the bone to form an effective antibacterial concentration, but also the method is easy to implement, simple to prepare, and convenient to use.

The invention discloses an application of a benzo-aza derivative in preparation of a medicine for preventing or treating atherosclerosis, the benzo-aza derivative is a compound with a chemical structure as shown in a formula I, or a pharmaceutically acceptable salt, a precursor or a metabolite of the compound, and in the formula I, X is halogen or H. The traditional Chinese medicine composition has the technical effects that the plaque stabilizing effect is obvious, the plaque composition is improved, the necrosis core area in the plaque is reduced, the total plaque load can be effectively reduced, the lesion progress is delayed / reversed, the dependence on lipid reduction is avoided, the treatment blank is filled, a brand new plaque stabilizing treatment strategy is provided, and the clinical problem of residual cardiovascular risks is expected to be solved. The safety is good, the organ specificity is high, and the whole body toxicity is low. The invention provides a new treatment normal form, new use of old medicines and large clinical transformation potential, and can be used as a supplement and enhancement of a basic therapy (such as statin lipid reduction) to form a combined treatment scheme of lipid reduction and spot stabilization, thereby realizing multi-channel cooperative control of atherosclerosis.

This invention relates to the fields of biomedical engineering and drug delivery technology, specifically disclosing a novel targeted drug delivery system based on rosehip extracellular vesicles, comprising: preparing rosehip-derived extracellular vesicles; preparing drug-loaded vesicles; and preparing targeted modified drug-loaded vesicles. This invention utilizes the specific downregulation of stem cell-related pathways by rosehip components, while simultaneously leveraging doxorubicin to kill conventional tumor cells, forming a complementary therapeutic mechanism to fundamentally reduce the risk of tumor recurrence. The phenylboronic acid group of DSPE-PEG-PBA specifically recognizes sialic acid overexpressed on the surface of tumor cells, significantly increasing drug accumulation in tumor tissues while reducing distribution in normal tissues. By leveraging the natural biocompatibility and low immunogenicity of RHNVs, combined with the long-circulating properties of the PEG chain, systemic toxicity is minimized while ensuring delivery efficiency, particularly reducing the cardiotoxicity and bone marrow suppression of doxorubicin.

The invention relates to the technical field of medicine, in particular to a preparation method and application of a nano platform targeting tumor endogenous SOX9, and the technical key points are as follows: the preparation method comprises the following steps: S1, synthesizing hollow mesoporous silica nanoparticles; s2, preparing the organic silicon nanoparticles loaded by the Monensin; and S3, extraction of the macrophage membrane and preparation of the coating. The carrier prepared by the preparation method and the tumor endogenous SOX9 targeting nano platform are applied to the preparation of antitumor drugs. In the scheme of the invention, a novel nano delivery platform prepared based on Monensin is expected to become a powerful candidate drug for inhibiting SOX9 in gastric cancer treatment. According to the scheme, Monensin is delivered through a mesoporous silica platform camouflaged by a macrophage cell membrane, drug release can be accurately controlled, the targeting property and bioavailability of drugs can be effectively improved, and the scheme of the invention provides an innovative strategy with potential clinical application value for gastric cancer treatment.

The present invention discloses a tripterygium wilfordii nanoliposome, which is composed of a liposome core and an outer layer of wrapping material, wherein the liposome core contains a lipid material, TPP-TPGS and tripterygium wilfordii, and the wrapping material is hyaluronic acid, wherein the hyaluronic acid can actively target the overexpressed CD44 receptor on the surface of tumor cells, thereby increasing the accumulation of the drug carried in the tumor site, and the TPP-TPGS can further deliver the drug to the mitochondria, thereby increasing the active oxygen content of tumor cells, reducing the mitochondrial membrane potential, destroying the mitochondrial function, and further causing apoptosis. Therefore, the liposome is a tumor cell and mitochondrial dual-level targeting liposome, which is beneficial to reducing the toxicity of tripterygium wilfordii and improving the efficacy of the drug against intrahepatic cholangiocarcinoma.

This invention discloses a nystatin microsphere with targeted enhanced antifungal function, its preparation method, and its application. The microsphere uses sodium alginate as a carrier, internally encapsulating the antifungal drug nystatin. The surface is covalently modified with the β-glucan binding domain of the Dectin-1 protein, constructing a smart drug delivery system with fungal targeting function. The microsphere preparation process is simple and reproducible, and can be scalable using an emulsion-ionic crosslinking method combined with protein coupling technology. In vitro characterization shows that the microspheres have uniform particle size and stable dispersion, and Dectin-1 modification significantly enhances their specific binding ability against Candida albicans. This targeted delivery system, while successfully preserving drug activity, significantly improves the antifungal efficiency of nystatin through Dectin-1-mediated targeting, achieving efficacy close to that of free drug, and providing a new strategy for constructing highly efficient and long-acting antifungal agents.

Compounds based on sealin-4 binding peptide (C4BP) have been specifically designed for radiopharmaceuticals. Specifically, C4BP-integrated compounds and compositions have been designed for use specifically in the detection and treatment of pancreatic cancer. Embodiments are compounds comprising a peptide, a spacer (or spacer-free), and a chelating agent, wherein the compound binds to CLDN4. The compounds can bind to metal radioisotopes to produce radiopharmaceuticals. The range of applications of these compounds includes diagnostic procedures, therapeutic interventions, and targeted delivery of radionuclides to tissues expressing CLDN4. Described herein are detailed methods of radiopharmaceuticals in combination with CPB for diagnosis, treatment, and targeted delivery in tissues expressing CLDN4.

The application relates to a MYH2-FIGN interaction blocking amino acid compound and an application thereof, and relates to the fields of polypeptide drugs and tumor prevention and treatment. The MYH2-FIGN interaction blocking amino acid compound is an amino acid sequence as shown in SEQ ID NO:1 or SEQ ID NO:3 or a polypeptide derivative thereof. The application further discloses a pharmaceutical composition containing the MYH2-FIGN interaction blocking amino acid compound and a pharmaceutically acceptable carrier. The application first designs a polypeptide drug targeting the MYH2-FIGN interaction interface, and compared with traditional small molecules, the polypeptide drug has specificity for MYH2-FIGN interaction inhibition, and through fusion of an iRGD peptide, not only is the polypeptide cell penetration problem solved, but also the polypeptide drug is endowed with tumor targeting, the bioavailability of the drug is improved, and the systemic toxicity is reduced. The polypeptide drug can adopt various drug dosage forms, and the preparation process is simple.

The present invention discloses a gel factor loaded with anti-inflammatory drugs, a hydrogel, and a preparation method and application thereof, which belongs to the field of gel materials and medicine, wherein the structural formula of the gel factor is: The hydrogel prepared by using the gel factor can be used to deliver drugs to the inflamed colon mucosa, and shows a highly effective therapeutic effect after enema in an acute colitis mouse model. With excellent targeting ability and high therapeutic efficiency, the hydrogel provides a powerful platform for the treatment of inflammatory bowel disease while reducing systemic toxicity.

The invention discloses a full-nutrient formula mousse product special for tumor patients and a preparation method, and relates to the technical field of full-nutrient mousse, and the preparation method comprises the following steps: preparing lipidosome coated with nutrients, preparing nanoparticles coated with trace elements, modifying the surfaces of the lipidosome and the nanoparticles with a targeting substance, and preparing the full-nutrient formula mousse product. All the raw materials are mixed to prepare the full-nutrient mousse, and the full-nutrient mousse has the advantages that some nutrients which have an auxiliary effect on tumor treatment but are poor in stability or difficult to absorb in gastrointestinal tracts are wrapped in nano-particles through a nanotechnology; the surface of the nano-particles is modified with a targeting substance which can be specifically recognized and taken by tumor tissues or immune cells, so that the concentration of the nutrients in a tumor microenvironment or an immune regulation site is improved, the action effect of the nutrients is enhanced, vitamin C is prepared into a nano-liposome wrapped form and is added into mousse, and the mousse has the effect of improving the tumor microenvironment or immune regulation site. Liposome can protect vitamin C from being damaged by gastric acid and enable the vitamin C to be more effectively absorbed by intestinal tracts.

The invention discloses a breast cancer antibody drug conjugate based on a targeted HER2 receptor and application of the breast cancer antibody drug conjugate in the technical field of antibody drug conjugates, the breast cancer antibody drug conjugate comprises a monoclonal antibody, the monoclonal antibody is coupled with a cytotoxic drug through a polymer, the monoclonal antibody is trastuzumab, and the monoclonal antibody is an HER2 receptor. The cytotoxic drug is maytansine DM1 with a tubulin synthesis inhibition effect, the polymer comprises a polyaspartic acid chain, a plurality of maleimide groups are grafted on side branch carboxyl of the polyaspartic acid chain, and Fc-III-4C peptide in the polymer is combined with an Fc segment of trastuzumab through a high affinity effect, so that the polymer can be used for inhibiting microtubulin synthesis. And the monoclonal antibody-polymer-cytotoxic drug conjugate T-NPLA-DM1 is formed by using the monoclonal antibody-polymer-cytotoxic drug conjugate. The antibody drug conjugate is novel and effective, and the drug loading capacity of a single drug molecule is improved by using the polyamino acid as the drug conjugate, so that the drug-antibody ratio of the antibody drug conjugate is improved, and the lethality of an anti-tumor drug to HER2 positive breast cancer tumor cells is enhanced.

The present invention discloses a method for preparing a CRISPR / Cas9 gene delivery system. The particle size of the gene delivery system is about 180-200 nm, the carrier is a two-dimensional iron sulfide nanosheet, CRISPR / Cas9 is used for gene therapy, and the two-dimensional iron sulfide nanosheet is used to induce ferroptosis and enhance photothermal therapy. The preparation method includes chelation, reactant mixing, solvent thermal reaction, FeS / CRISPR / Cas9 complex preparation, red blood cell membrane extraction, tumor cell membrane extraction, and hybrid membrane modification steps. The present invention prepares a CRISPR / Cas9 gene delivery system, and the synthesized product has stability and repeatability, which is conducive to biomedical research on gene delivery and synergistic tumor therapy.

The invention discloses a Y-type polyethylene glycol conjugate nanoparticle as well as a synthesis method and application thereof. The synthesis method of the Y-type polyethylene glycol conjugate nanoparticle comprises the following steps: combining Y-type polyethylene glycol with adriamycin to synthesize a Y-type PEG-DOX conjugate; and dissolving the Y-type PEG-DOX conjugate in a PBS (Phosphate Buffer Solution), and carrying out self-assembly under ultrasonic oscillation to form the Y-type polyethylene glycol conjugate nanoparticles. The application mainly refers to application of the Y-type polyethylene glycol conjugate nanoparticle in preparation of drugs for treating cancers, especially application of the Y-type polyethylene glycol conjugate nanoparticle in preparation of drugs for treating pancreatic cancer. The nanoparticles synthesized by the method can improve the water solubility of DOX, improve the in-vivo and in-vitro stability of drugs, improve the enrichment of DOX at tumor sites and reduce the toxicity of the whole body, thereby improving the treatment effect on solid tumors.

A biological material comprising a first porous polymer, a second non-porous polymer, and a therapeutic agent, and a method of using the same for treating a condition are disclosed. The biomaterials disclosed herein may be, for example, surgical articles. Implanting the biomaterials disclosed herein in a subject can treat, for example, cancer.

This invention discloses a ZIF-8 nanomedicine delivery system co-loaded with doxorubicin and siTDRKH, its preparation method, and its applications, belonging to the fields of biomedicine and nanomaterials technology. The nanomedicine delivery system uses the zeolite imidazole ester framework material ZIF-8 as a carrier. Its porous structure encapsulates the chemotherapeutic drug doxorubicin within the framework, and small interfering RNA targeting the TDRKH gene is loaded onto the surface through electrostatic adsorption. This structure exhibits high pH responsiveness: it remains stable under normal physiological conditions (pH 7.4), preventing premature drug leakage; upon entering the slightly acidic environment of a tumor (pH 6.5) or a lysosomal environment (pH 5.0), the ZIF-8 framework immediately disintegrates, achieving targeted and synergistic release of the loaded drug.

This invention is a divisional application of application number 202010500967.1. The invention relates to a layered double hydroxide material system, its preparation method, and its application, specifically the application of LDH / EDTA layered double hydroxide materials in the preparation of antitumor drugs. The LDH / EDTA layered double hydroxide material is a zinc-aluminum layered double hydroxide loaded with ethylenediaminetetraacetic acid (EDTA); in the EDTA-loaded zinc-aluminum layered double hydroxide, EDTA is anion-exchange-intercalated into the interlayer space of the zinc-aluminum layered double hydroxide; the surface of the EDTA-loaded zinc-aluminum layered double hydroxide is positively charged.

The invention discloses a trabectedin-loaded nano-micelle and oxaliplatin-loaded drug combination composition and application, and relates to the technical field of delivery and drug combination, and the trabectedin-loaded nano-micelle and oxaliplatin-loaded drug combination composition comprises trabectedin-loaded nano-micelle and oxaliplatin. The invention also discloses an application of the combined pharmaceutical composition in preparation of antitumor drugs. According to the invention, a pH-sensitive amphiphilic biodegradable material (such as PCL-PEOz) and a chemical drug are self-assembled to form stable micelles, so that the bioavailability of the drug is improved, the critical concentration of the micelles is reduced, and long-acting circulation in vivo is realized; the system can be combined with oxaliplatin for use, so that the sensitivity of tumor cells to oxaliplatin is promoted, the synergistic effect of chemotherapy and immunotherapy is exerted, the treatment effect of malignant tumors is improved, and the tumor microenvironment is improved.